Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

CBD: What is it? A former DEA agent explains.

Dennis Wichern
Meds
April 4, 2019
259 Shares
Share
Tweet
Share

What is CBD?

Cannabidiol or CBD for short is made from either the marijuana plant that contains tetrahydrocannabinol (THC) or hemp which contains little to any THC. “Hemp-derived” means that the CBD generally contains less than 0.3% THC while “marijuana-derived” contains higher amounts of THC. It is THC — and not CBD — is the primary psychoactive or intoxicating component of marijuana. CBD can also be manufactured synthetically.

CBD is routinely sold as an oil extract commonly referred to as CBD oil.

Overall, CBD is used by consumers as an over-the-counter alternative medicine to self-treat a variety of ills such as acne, addiction, anxiety or stress, chronic pain, depression, epilepsy, glaucoma, insomnia, loss of appetite, muscle spasms, Parkinson’s disease and more. Additionally, it is used as an additive in some food and beauty products to address the above conditions and also used in some forms to treat certain animal conditions.

What’s the FDA’s view?

This past June, the FDA approved the first-ever CBD drug, Epidiolex, a Schedule V medication to help treat two rare forms of epilepsy, Dravet syndrome and Lennox-Gestaut syndrome in patients two years of age and older. Epidiolex contains less than 0.15% THC with a list price around $32,500 annually, however, its insurance costs are significantly lower.

On June 25, 2018, FDA Commissioner Scott Gottlieb M.D. released a statement citing the agency’s approval of Epidiolex by stating: “This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies. Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients.”

In the same statement, Dr. Gottlieb cautioned that the FDA is also “prepared to take action when we see the illegal marketing of CBD-containing products with serious, unproven medical claims. Marketing unapproved products, with uncertain dosages and formulations, can keep patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”

What about the CDC?

According to the CDC, “Cannabis-based products, such as man-made cannabinoid-based medications, may help prevent and ease nausea caused by chemotherapy.” Short-term use has been shown to help adults with multiple sclerosis-related muscle spasms.

Regarding its use for chronic pain, the CDC finds that uncertainty remains about its effectiveness and that “more information is needed to know if pain relief from cannabis is any better or worse than other pain management options, such as over over-the-counter drugs like ibuprofen or alternative treatments like occupational therapy.”

How about the DEA?

When Epidiolex was approved in 2018, DEA concluded its press announcement on September 27, 2018 with the following statement: “Marijuana and CBD derived from marijuana remain against the law, except for the limited circumstances that it has been determined there is a medically approved benefit. In those instances, such as here, the drug will be made appropriately available to the public for medical use. ”

The DEA’s view of CBD is that the drug is illegal due to the definition of “marihuana” found in Title 21 United States Code §802 (16). Two things to keep in mind, the Controlled Substances Act (“CSA”) was made law in 1970 and has changed little in almost 50 years and secondly, with the DEA’s focus on cartels, gangs, fentanyl and the opioid crisis, CBD oils and products may likely never be on DEA’s radar due to the agency’s limited resources.

Is it legal?

It depends.

The federal Agriculture Improvement Act of 2018 that was signed into law on December 20, 2018, removed hemp or low content THC cannabis from the Controlled Substances Act, which means that it is no longer an illegal substance under federal law. The same act defined hemp as cannabis that contained less than 0.3% of THC but made no mention of CBD.

CBD is currently legal in 30 states that have legalized marijuana use and 17 other states that have legalized some type of CBD.

Standard dosage unit?

There are currently no established standards for safely producing CBD oil or a standard dosage unit. As a 2017 published JAMA study found, “Among CBD products purchased online, a wide range of CBD concentrations was found, consistent with the lack of an accepted dose. Of tested products, 26% contained less CBD than labeled, which could negate any potential clinical response.”

“The over labeling of CBD products in this study is similar in magnitude to levels that triggered warning letters to 14 businesses in 2015-2016 from the US Food and Drug Administration, suggesting that there is a continual need for federal and state regulatory agencies to take steps to ensure label accuracy of these consumer products.”

Last thoughts

CBD oil derived from hemp (marijuana with a THC content of less than 0.3% as defined federally) looks promising as a medicine especially as evidenced by the FDA’s recent approval of Epidiolex.

Medical professionals considering utilizing CBD oil should review the latest scientific studies and ensure that their preferred product is manufactured to the highest standards, legal in their state and the exact contents of the drugs are known.

Dennis Wichern is a retired DEA agent.

Image credit: Shutterstock.com

Prev

It is time for physicians to reclaim the power of touch

April 4, 2019 Kevin 3
…
Next

When did people’s feelings start mattering more than patient safety?

April 4, 2019 Kevin 14
…

Tagged as: Medications, Oncology/Hematology

Post navigation

< Previous Post
It is time for physicians to reclaim the power of touch
Next Post >
When did people’s feelings start mattering more than patient safety?

More by Dennis Wichern

  • Telemedicine should be easy. Here’s why it’s not.

    Dennis Wichern
  • How to avoid negative press and fines during the opioid crisis

    Dennis Wichern
  • Kratom: harmless herbal supplement or dangerous drug?

    Dennis Wichern

Related Posts

  • A DEA agent explains how to fight the opioid crisis and mitigate DEA risk

    Dennis Wichern
  • 5 hidden consequences of chronic pain

    Toni Bernhard, JD
  • 5 things I wish I had known earlier about chronic pain

    Tom Bowen
  • Using low-dose naltrexone to treat pain

    Alex Smith
  • Blame the pain, not the opioids

    Angelika Byczkowski
  • On the internet, you are looking for something to make you angry

    Judson Ellis

More in Meds

  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Caught in the middle: How health insurance companies influence cancer drug selection

    Paul Pender, MD
  • Timely treatment decisions: the promise of surrogate markers

    Layla Parast, PhD
  • Most Popular

  • Past Week

    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • From physician to patient: one doctor’s journey to finding purpose after a devastating injury

      Stephanie Pearson, MD | Physician
    • An unspoken truth about non-compete clauses in medicine

      Harry Severance, MD | Policy
    • Fostering the next (diverse) generation of clinicians

      Imamu Tomlinson, MD, MBA | Physician
    • Healing through love and spirituality

      John T. James, PhD | Conditions
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Why are doctors sued and politicians aren’t?

      Kellie Lease Stecher, MD | Physician
    • The Titanic sinking: a metaphor for the impending collapse of medicine

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD & Shreekant Vasudhev, MD | Physician
  • Recent Posts

    • Rescuing primary care: the role of health administrators [PODCAST]

      The Podcast by KevinMD | Podcast
    • Breaking down barriers: How technology is improving diabetes management in underserved communities

      Anonymous | Conditions
    • From penicillin to digital health: the impact of social media on medicine

      Homer Moutran, MD, MBA, Caline El-Khoury, PhD, and Danielle Wilson | Social media
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • How to overcome telemedicine’s biggest obstacles

      Harvey Castro, MD, MBA | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Investigational ALS Drug May Have Clinical Benefit, FDA Staff Says
  • Cases of Deadly Fungus Tripled in Past Few Years, CDC Says
  • Small Gains in Cardiorespiratory Fitness Track With Improved Longevity
  • Improved OS With Hyperfractionated RT in Recurrent Nasopharyngeal Carcinoma
  • GPT-4 Is Here. How Can Doctors Use Generative AI Now?

Meeting Coverage

  • Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor
  • New Approaches in the Bladder-Sparing Paradigm
  • Response Rates in Hidradenitis Suppurativa Continue to Climb With New Therapies
  • Another Win for a JAK Inhibitor in Alopecia Areata
  • Biologic Switch Revs Up Response in Plaque Psoriasis
  • Most Popular

  • Past Week

    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • From physician to patient: one doctor’s journey to finding purpose after a devastating injury

      Stephanie Pearson, MD | Physician
    • An unspoken truth about non-compete clauses in medicine

      Harry Severance, MD | Policy
    • Fostering the next (diverse) generation of clinicians

      Imamu Tomlinson, MD, MBA | Physician
    • Healing through love and spirituality

      John T. James, PhD | Conditions
  • Past 6 Months

    • The hidden dangers of the Nebraska Heartbeat Act

      Meghan Sheehan, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • Why are doctors sued and politicians aren’t?

      Kellie Lease Stecher, MD | Physician
    • The Titanic sinking: a metaphor for the impending collapse of medicine

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD & Shreekant Vasudhev, MD | Physician
  • Recent Posts

    • Rescuing primary care: the role of health administrators [PODCAST]

      The Podcast by KevinMD | Podcast
    • Breaking down barriers: How technology is improving diabetes management in underserved communities

      Anonymous | Conditions
    • From penicillin to digital health: the impact of social media on medicine

      Homer Moutran, MD, MBA, Caline El-Khoury, PhD, and Danielle Wilson | Social media
    • Healing the damaged nurse-physician dynamic

      Angel J. Mena, MD and Ali Morin, MSN, RN | Policy
    • How to overcome telemedicine’s biggest obstacles

      Harvey Castro, MD, MBA | Physician
    • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

      Mohammed Umer Waris, MD | Policy

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

CBD: What is it? A former DEA agent explains.
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...